Composition with effect of preventing and / or improving non-alcoholic fatty liver and preparation method thereof

Abstract

The invention belongs to the technical field of functional foods and health-care foods, and particularly relates to a composition with an effect of preventing and / or improving non-alcoholic fatty liver and a preparation method of the composition. The composition comprises an eggshell membrane extract, lemon concentrated powder, ganoderma sinensis powder and beet root powder. The composition prepared by the invention can be used for effectively relieving liver injury, liver lipid metabolism disorder and liver oxidative stress by reducing the liver index and weight change rate of a mouse, reducing the contents of AST and ALT in serum of the mouse and the contents of TC, TG and MDA in the liver and improving the content of SOD in the liver, so that the effect of improving the non-alcoholic fatty liver is achieved.

Description

Technical Field

[0001] This invention belongs to the field of functional food and health food technology, specifically relating to a composition with the effect of preventing and / or improving non-alcoholic fatty liver and its preparation method. Background Technology

[0002] Non-alcoholic fatty liver disease (NAFLD) is a multi-system disease characterized by abnormal fat accumulation in the liver without a history of excessive alcohol consumption. It often causes abnormalities in extrahepatic organs and regulatory pathways. NAFLD is an important risk factor for both intrahepatic diseases (cirrhosis, liver failure, hepatocellular carcinoma) and extrahepatic diseases (type 2 diabetes, cardiovascular disease, chronic kidney disease, cerebrovascular disease, colorectal cancer).

[0003] Obesity (especially abdominal obesity) is the leading risk factor for NAFLD. This is primarily because obese patients often have abnormal fat metabolism. Obese individuals experience active fat breakdown, releasing large amounts of free fatty acids into the bloodstream. Some of these free fatty acids are absorbed by the liver, far exceeding its normal metabolic capacity, leading to fat accumulation in liver cells. Furthermore, most obese patients have insulin resistance, preventing insulin from effectively promoting glucose uptake by cells and promoting fat synthesis, further exacerbating fat accumulation in the liver.

[0004] Currently, conventional treatment strategies for NAFLD include physical exercise and dietary adjustments. Clinically, treatment primarily involves insulin sensitizers, lipid-lowering agents, and liver protection, but there are no definitively effective drugs. NAFLD presents challenges due to its long treatment duration, poor patient adherence, and the fact that some patients, due to insufficient understanding, lack of physical activity, or dietary indiscretions, fail to follow the physician's prescribed interventions, leading to the malignant transformation of NAFLD. Summary of the Invention

[0005] Therefore, the present invention provides a composition that, on the one hand, can reduce the liver index and weight change rate in mice with non-alcoholic fatty liver disease and reduce intrahepatic fat; on the other hand, it can improve liver damage and liver oxidation caused by non-alcoholic fatty liver disease by reducing the levels of serum ALT, AST, liver TG, TC, and MDA and increasing the levels of liver SOD.

[0006] To achieve the above objectives, the technical content of the present invention is as follows:

[0007] On the one hand, the present invention provides a composition having the effect of preventing and / or improving non-alcoholic fatty liver disease, comprising eggshell membrane extract, lemon concentrate powder, Ganoderma lucidum powder and beetroot powder.

[0008] Preferably, the composition provided by the present invention for preventing and / or improving non-alcoholic fatty liver disease comprises, by weight, 30-50 parts eggshell membrane extract, 5-15 parts lemon concentrate powder, 20-40 parts Ganoderma lucidum powder and 15-35 parts beetroot powder.

[0009] More preferably, the composition having the effect of preventing and / or improving non-alcoholic fatty liver disease comprises, by weight, 35-45 parts eggshell membrane extract, 8-12 parts lemon concentrate powder, 25-35 parts Ganoderma lucidum powder and 20-30 parts beetroot powder.

[0010] Preferably, the weight ratio of the eggshell membrane extract to the lemon concentrate is (2-10):1; more preferably, the weight ratio of the eggshell membrane extract to the lemon concentrate is (2.3-7):1; and even more preferably, the weight ratio of the eggshell membrane extract to the lemon concentrate is 4:1.

[0011] Preferably, the weight ratio of the eggshell membrane extract to the Ganoderma lucidum powder is (0.75-2.5):1; more preferably, the weight ratio of the eggshell membrane extract to the Ganoderma lucidum powder is (0.8-1.8):1; and even more preferably, the weight ratio of the eggshell membrane extract to the Ganoderma lucidum powder is 1.3:1.

[0012] Preferably, the weight ratio of the eggshell membrane extract to the beetroot powder is (0.85-3.3):1; more preferably, the weight ratio of the eggshell membrane extract to the beetroot powder is (1-2.5):1; and even more preferably, the weight ratio of the eggshell membrane extract to the beetroot powder is 1.6:1.

[0013] Preferably, the composition comprises, by weight, 40 parts eggshell membrane extract, 10 parts lemon concentrate powder, 30 parts Ganoderma lucidum powder and 25 parts beetroot powder.

[0014] Preferably, the eggshell membrane extract is made from eggshells through processes such as shell-membrane separation (discarding the shell and taking the membrane), sterilization, hydrolysis, mixing, drying, and grinding, wherein the total content of 16 amino acids is not less than 34g / 100g.

[0015] The 16 amino acids specifically include aspartic acid, threonine, serine, glutamic acid, glycine, alanine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, lysine, histidine, arginine, and proline.

[0016] Preferably, the lemon concentrate is prepared by pure water extraction, concentrated spray drying, and fresh lemon, wherein the content of senna-10% is not less than 10%.

[0017] Preferably, the Ganoderma lucidum powder is prepared by water extraction, concentration and spray drying of Ganoderma lucidum, wherein the polysaccharide content is not less than 10%.

[0018] Preferably, the beetroot powder is prepared by water extraction of beetroot, followed by concentrated spray drying, with a specification of 10:1.

[0019] On the other hand, the present invention provides a method for preparing the above composition, comprising weighing eggshell membrane extract, lemon concentrate powder, Ganoderma lucidum powder and beetroot powder, mixing them and then sterilizing them with ultraviolet light to obtain the composition.

[0020] Preferably, the ultraviolet sterilization time is 30-50 min; the mixing time is 35-50 min.

[0021] More preferably, the ultraviolet sterilization time is 40 min; the mixing time is 45 min.

[0022] The use of the above composition in the preparation of products for the prevention and / or improvement of non-alcoholic fatty liver disease.

[0023] Compared with the prior art, the present invention has the following advantages:

[0024] The raw materials used in this invention are analyzed as follows:

[0025] Eggshell membrane extract has multiple physiological functions, including promoting wound healing, anti-inflammation, antibacterial properties, lowering blood sugar, and anti-oxidation.

[0026] Lemons contain a large number of functional components, such as pectin, flavonoids (senna glycosides), polyphenols, dietary fiber, vitamins, limonene, and volatile oils, which have high health and medicinal value.

[0027] Ganoderma lucidum is an edible fungus containing chemical components such as triterpenoids, polysaccharides, steroids, and fatty acids. It has pharmacological effects such as anti-tumor, antioxidant, antibacterial, anti-inflammatory and analgesic, liver protection and detoxification, and immune regulation.

[0028] Beetroot contains highly active pigments, betaine pigments, ascorbic acid, carotenoids, polyphenols, flavonoids, saponins, and high levels of nitrates, among other nutrients, and has antioxidant, anti-inflammatory, anti-cancer, and liver-protective effects.

[0029] 1 The composition provided by the present invention for preventing and / or improving non-alcoholic fatty liver disease includes four raw materials: eggshell membrane extract, lemon concentrate powder, beetroot powder and Ganoderma lucidum powder. The four raw materials work synergistically to significantly reduce the rate of weight change and liver index in NAFLD mice. Furthermore, physical and chemical index detection shows that it can significantly reduce the content of TC and TG in the liver, thereby achieving the effect of reducing the liver fat content in non-alcoholic fatty liver disease.

[0030] 2. The composition provided by the present invention can reduce the levels of AST and ALT in the serum of NAFLD mice, thereby improving liver damage caused by non-alcoholic fatty liver disease.

[0031] 3. The composition provided by the present invention can reduce the content of MDA and increase the content of SOD in the liver, effectively alleviate lipid metabolism disorders and liver oxidative stress, and relieve liver inflammation.

[0032] 4. The composition provided by the present invention uses new resource foods or food and medicine homologous raw materials as raw materials, which can be taken daily without side effects. Attached Figure Description

[0033] Figure 1 The results show the rate of change in body weight of mice in the blank group, model group, Examples 1-5 and Comparative Examples 1-7. Different letters represent significant differences between groups, P < 0.05.

[0034] Figure 2 The results are for the liver index of mice in the blank group, model group, Examples 1-5 and Comparative Examples 1-7. Different letters represent significant differences between the groups, P < 0.05. Detailed Implementation

[0035] The following non-limiting embodiments are intended to enable those skilled in the art to gain a more comprehensive understanding of the present invention, but do not limit the invention in any way. The following content is merely an exemplary description of the scope of protection claimed by the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, and such changes should also fall within the scope of protection claimed by the present invention.

[0036] When numerical ranges are given in the embodiments, it should be understood that, unless otherwise stated in the invention, both endpoints of each numerical range and any value between the two endpoints may be selected. Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0037] The present invention will be further described below by way of specific embodiments. Unless otherwise specified, all chemical reagents used in the embodiments of the present invention are obtained through conventional commercial channels. Products from different manufacturers do not have a significant impact on the effectiveness.

[0038] Eggshell membrane extract (total amino acids 34.81g / 100g) was purchased from Gansu Yishengxiang Biotechnology Co., Ltd.; lemon concentrate powder (10% senna glycosides) was purchased from Tuofeng Powder Technology (Kunshan) Co., Ltd.; beetroot powder (specification 10:1, water extraction, concentrated spray drying) was purchased from Xi'an Senran Bioengineering Co., Ltd.; Ganoderma lucidum powder (polysaccharide 10%) was purchased from Zhejiang Yangzhikang Biotechnology Co., Ltd.; Astragalus powder (specification 10:1, water extraction, low temperature vacuum drying) was purchased from Xi'an Zhongyan Kangze Biotechnology Co., Ltd.

[0039] Example 1

[0040] This embodiment provides a composition with the effect of preventing and / or improving non-alcoholic fatty liver disease, comprising 40 parts eggshell membrane extract, 10 parts lemon concentrate powder, 30 parts Ganoderma lucidum powder and 25 parts beetroot powder.

[0041] The total weight of the composition in the example is 300g, and its preparation method is as follows:

[0042] (1) Weighing: Weigh the four raw materials according to the proportions and set them aside;

[0043] (2) Sterilization: The raw materials weighed in step (1) are put into a ribbon mixer and mixed for 45 minutes, and then sterilized with ultraviolet light for 40 minutes to obtain the composition.

[0044] Example 2

[0045] This embodiment provides a composition that has the effect of preventing and / or improving non-alcoholic fatty liver disease, comprising 30 parts of eggshell membrane extract, 5 parts of lemon concentrate powder, 20 parts of Ganoderma lucidum powder and 15 parts of beetroot powder.

[0046] The total weight of the composition in the example is 300g, and its preparation method is the same as that in Example 1.

[0047] Example 3

[0048] This embodiment provides a composition with the effect of preventing and / or improving non-alcoholic fatty liver disease, comprising 50 parts eggshell membrane extract, 8 parts lemon concentrate powder, 35 parts Ganoderma lucidum powder and 20 parts beetroot powder.

[0049] The total weight of the composition in the example is 300g, and its preparation method is the same as that in Example 1.

[0050] Example 4

[0051] This embodiment provides a composition with the effect of preventing and / or improving non-alcoholic fatty liver disease, comprising 45 parts eggshell membrane extract, 12 parts lemon concentrate powder, 25 parts Ganoderma lucidum powder and 35 parts beetroot powder.

[0052] The total weight of the composition in the example is 300g, and its preparation method is the same as that in Example 1.

[0053] Example 5

[0054] This embodiment provides a composition with the effect of preventing and / or improving non-alcoholic fatty liver disease, comprising 35 parts eggshell membrane extract, 15 parts lemon concentrate powder, 40 parts Ganoderma lucidum powder and 30 parts beetroot powder.

[0055] The total weight of the composition in the example is 300g, and its preparation method is the same as that in Example 1.

[0056] Comparative Example 1

[0057] This comparative example provides a composition that differs from Example 1 in that it does not include eggshell membrane extract, but includes 10 parts lemon concentrate powder, 30 parts Ganoderma lucidum powder and 25 parts beetroot powder.

[0058] The total weight of the comparative composition was 300g, and its preparation method was the same as that in Example 1.

[0059] Comparative Example 2

[0060] This comparative example provides a composition that differs from Example 1 in that it does not include Ganoderma lucidum powder, but includes 40 parts of eggshell membrane extract, 10 parts of lemon concentrate powder and 25 parts of beetroot powder.

[0061] The total weight of the comparative composition was 300g, and its preparation method was the same as that in Example 1.

[0062] Comparative Example 3

[0063] This comparative example provides a composition that differs from Example 1 in that it does not include beetroot powder, but includes 40 parts of eggshell membrane extract, 10 parts of lemon concentrate powder, and 30 parts of Ganoderma lucidum powder.

[0064] The total weight of the comparative composition was 300g, and its preparation method was the same as that in Example 1.

[0065] Comparative Example 4

[0066] This comparative example provides a composition that differs from Example 1 in that it does not include lemon concentrate powder, but includes 40 parts eggshell membrane extract, 30 parts Ganoderma lucidum powder and 25 parts beetroot powder.

[0067] The total weight of the comparative composition was 300g, and its preparation method was the same as that in Example 1.

[0068] Comparative Example 5

[0069] This comparative example provides a composition that differs from Example 1 in that it increases the content of Ganoderma lucidum powder, namely, it includes 40 parts of eggshell membrane extract, 10 parts of lemon concentrate powder, 80 parts of Ganoderma lucidum powder and 25 parts of beetroot powder.

[0070] The total weight of the comparative composition was 300g, and its preparation method was the same as that in Example 1.

[0071] Comparative Example 6

[0072] This comparative example provides a composition that differs from Example 1 in that it increases the content of lemon concentrate, namely, it includes 40 parts eggshell membrane extract, 40 parts lemon concentrate, 30 parts Ganoderma lucidum powder, and 25 parts beetroot powder.

[0073] The total weight of the comparative composition was 300g, and its preparation method was the same as that in Example 1.

[0074] Comparative Example 7

[0075] This comparative example provides a composition that differs from Example 1 in that beetroot powder is replaced with astragalus powder, namely, it includes 40 parts eggshell membrane extract, 10 parts lemon concentrate powder, 30 parts Ganoderma lucidum powder and 25 parts astragalus powder.

[0076] The total weight of the comparative composition was 300g, and its preparation method was the same as that in Example 1.

[0077] Experiment Example 1: Mouse Experiment

[0078] The kits for superoxide dismutase (SOD), triglycerides (TG), total cholesterol (TC), malondialdehyde (MDA), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were purchased from Nanjing Jiancheng Biotechnology Institute, with catalog numbers A001-1-2, A110-1-1, A111-1-1, A003-1-2, C009-2-1, and C010-2-1, respectively.

[0079] 1.1 Animal grouping, model establishment, and drug administration

[0080] SPF-grade male C57BL / 6 mice were acclimatized for 3 days, and 10 mice were randomly selected to receive a standard diet (purchased from Xiaoshuyoutai (Beijing) Biotechnology Co., Ltd.) as the blank control group. The remaining mice were given a high-fat diet (basal diet, 15% sucrose, 15% lard, purchased from Xiaoshuyoutai (Beijing) Biotechnology Co., Ltd.) for 12 weeks to establish the model. The mice were then randomly divided into the model group, the Examples 1-5 groups, and the Comparative Examples 1-7 groups. The experimental group mice were given the corresponding drug intervention at the beginning of the modeling process by gavage (10 mg / kg), once a day, for 12 consecutive weeks until the modeling was completed.

[0081] 1.2 Indicator Testing

[0082] The mice in each group were carefully observed and recorded in terms of coat color, behavior, and diet. The weight of the mice was recorded twice (before the start of the experiment and after the modeling was completed), and the weight change rate at the intervention endpoint was calculated according to the formula.

[0083]

[0084] All mice were fasted for 12 hours after the last administration, and blood was collected from their eyeballs. The collected blood was centrifuged at 3000 rpm for 10 minutes at 4°C to obtain serum. ALT and AST levels were measured strictly according to the kit instructions. After blood collection from the eyeballs, mice were euthanized by cervical dislocation, and the livers were dissected, rinsed with pre-cooled physiological saline, blotted dry with filter paper, weighed, and the liver index was calculated according to the formula for comparison. The liver was homogenized with physiological saline at a ratio of 1:9, centrifuged at 3000 rpm for 10 minutes at 4°C, and the supernatant was collected for later use. TG, TC, SOD, and MDA levels were measured strictly according to the kit instructions.

[0085]

[0086] 1.3 Experimental Results

[0087] During the experiment, the mice were in good condition and no adverse reactions occurred. During the drug administration period, the mice in the model group were in poor condition compared with the blank control group, with dry and dull fur and poor appetite. Compared with the model group, the mice in Examples 1-5 and Comparative Examples 1-7 showed improvement.

[0088] Obesity is a significant contributing factor to NAFLD. Liver indices reflect the physiological state of the mouse liver; higher values ​​indicate higher fat content in the liver. The weight change rate and liver indices of each group of mice are shown below. Figure 1 and Figure 2Compared with the blank group, the body weight change rate and liver index of the model group were significantly increased, proving that the model was successfully established by feeding with a high-fat diet; compared with the model group, the body weight change rate and liver index of Examples 1-5 were significantly decreased, indicating that the samples of Examples 1-5 can reduce body weight gain and liver fat accumulation in mice with non-alcoholic fatty liver disease.

[0089] The difference between Comparative Examples 1-4 and Example 1 is that the raw materials in the latter are a combination of three of the raw materials, while the former is composed of... Figure 1 and 2 It can be seen that the weight change rate and liver index are significantly higher than those in Example 1, indicating that the four raw materials selected in this invention can achieve better weight reduction and liver weight reduction effects through synergistic combination.

[0090] The difference between Comparative Example 7 and Example 1 is that beetroot powder was replaced with astragalus powder containing polysaccharides and having liver-protective effects. Figure 1 It can be seen that the weight change rate of Comparative Example 7 was significantly higher than that of Example 1, indicating that beetroot powder, in combination with eggshell membrane extract, lemon concentrate, and Ganoderma lucidum powder, can better reduce the weight change rate in mice with non-alcoholic fatty liver disease and achieve the effect of reducing the weight of mice with non-alcoholic fatty liver disease. The difference between Comparative Example 5 and Example 1 is that the proportion of Ganoderma lucidum powder was increased; the difference between Comparative Example 6 and Example 1 is that the proportion of lemon concentrate was increased. Figure 1 It can be seen that the weight change rate of Comparative Examples 5-6 was significantly higher than that of Example 1, indicating that the higher the content of lemon concentrate powder and Ganoderma lucidum powder, the better the effect. Only within the appropriate ratio range can lemon concentrate powder, beetroot powder, eggshell membrane extract and Ganoderma lucidum powder work together to achieve the best effect of reducing weight and reducing liver fat accumulation.

[0091] Similarly, by Figure 2 It can be seen that the liver index of Comparative Examples 5-7 was significantly improved compared with Example 1, indicating that the four raw materials selected in this invention, namely beetroot powder, eggshell membrane extract, lemon concentrate powder, and Ganoderma lucidum powder, can better reduce liver fat accumulation in mice with non-alcoholic fatty liver disease when used in synergistic combination within a certain proportion.

[0092] In summary, the composition provided by this invention has the effect of reducing the body weight and liver fat content in mice with non-alcoholic fatty liver disease.

[0093] Serum AST and ALT primarily reflect the degree of hepatocyte damage. Generally speaking, elevated AST and ALT levels indicate that hepatocytes are damaged or dead, and they are the most commonly used blood indicators for monitoring NAFLD in clinical practice.

[0094] The serum AST and ALT levels in each group of this invention are shown in Table 1. Compared with the blank group, the ALT and AST levels in the model group were significantly increased, indicating that the hepatocytes of the mice in the model group had a certain degree of damage and necrosis. Compared with the model group, the AST and ALT levels in Examples 1-5 were significantly decreased, indicating that the composition provided by this invention effectively inhibits the activity of the two enzymes and reduces liver damage.

[0095] Compared with Example 1, the difference between Comparative Examples 1-4 is that the raw material combination is 3 kinds. As shown in Table 1, the AST and ALT contents of Comparative Examples 1-4 are significantly increased compared with Example 1. It can be seen that the four raw material combinations selected in this invention can better reduce the serum AST and ALT contents of mice by working together.

[0096] The difference between Comparative Example 5 and Example 1 is that the proportion of Ganoderma lucidum powder was increased. As shown in Table 1, although ALT was not significantly different from that in Example 1, AST was significantly higher than that in Example 1, indicating that Ganoderma lucidum powder and other raw materials can only achieve the optimal effect of reducing AST and ALT content when the proportions are within a suitable range. The difference between Comparative Example 6 and Example 1 is that the proportion of lemon concentrate powder was increased, and ALT and AST were significantly higher than in Example 1, indicating that the ratio of lemon concentrate powder and other raw materials affects the serum AST and ALT content of mice. The difference between Comparative Example 7 and Example 1 is that Astragalus powder was replaced with beetroot powder, and ALT and AST were significantly higher than in Example 1, indicating that only the combination of the four raw materials selected in this invention—eggshell membrane extract, lemon concentrate powder, Ganoderma lucidum powder, and beetroot powder—can better exert the effect of reducing serum ALT and AST content in mice.

[0097] Table 1 Serum AST and ALT levels

[0098]

[0099] Note: Compared with the blank group, #P<0.05, ##P<0.01; compared with the model group, +P<0.05, ++P<0.01; compared with Example 1, △P<0.05, △△P<0.01.

[0100] Elevated triglycerides (TG) in the liver are a direct cause and core marker of non-alcoholic fatty liver disease (NAFLD), while elevated total cholesterol (TC) is a common accompanying phenomenon in NAFLD, reflecting hepatic lipid metabolism disorders. Elevated TG concentrations are often accompanied by toxic metabolites, lipotoxicity, and liver damage. TC is mainly synthesized and stored in the liver. When NAFLD occurs, the liver's ability to synthesize TC increases, leading to elevated TC concentrations. Therefore, TG and TC levels are closely related to hepatic lipid accumulation.

[0101] The TG and TC contents of each group are shown in Table 2. Compared with the blank group, the TG and TC contents of the model group were significantly higher than those of the blank group, indicating that the fat content in the liver of the mice in the model group was high and the model was successfully established. Compared with the model group, the TG and TC contents of Examples 1-5 were significantly reduced, indicating that the composition provided by the present invention significantly improved the lipid metabolism disorder in the liver and inhibited the accumulation of fat in the liver.

[0102] The difference between Comparative Examples 1-4 and Example 1 lies in the combination of three raw materials. As shown in Table 2, the TG and TC contents are significantly higher than those in Example 1, indicating that the combination of four raw materials can better reduce the TG and TC contents in mouse liver. The difference between Comparative Examples 5 and 6 and Example 1 is that the proportions of Ganoderma lucidum powder and lemon concentrate powder are increased, respectively. The TC contents of both are significantly higher than those in Example 1, while the TG contents are not significantly different from those in Example 1, but the values ​​are higher. This indicates that when lemon concentrate powder, Ganoderma lucidum powder, eggshell membrane extract powder, and beetroot powder are in a certain ratio range, they can better reduce the TC and TG contents in mouse liver. The difference between Comparative Example 7 and Example 1 is that Astragalus powder is used instead of beetroot powder. Its TC and TG contents are significantly higher than those in Example 1, indicating that the combination of the four raw materials selected in this invention—eggshell membrane extract, lemon concentrate powder, Ganoderma lucidum powder, and beetroot powder—can better reduce the TC and TG contents in mouse liver.

[0103] In summary, the composition and ratio of raw materials selected in this invention are an optimal combination, which can exert a synergistic effect, reduce the concentration of TG and TC in the liver, reduce fat accumulation, and effectively alleviate lipid metabolism disorders.

[0104] Table 2. TG and TC content in liver tissue

[0105]

[0106] Note: Compared with the blank group, #P<0.05, ##P<0.01; compared with the model group, +P<0.05, ++P<0.01; compared with Example 1, △P<0.05, △△P<0.01.

[0107] The accumulation of free fatty acids in hepatocytes increases the mitochondrial β-oxidation rate, leading to an increase in the amount of reactive oxygen species (ROS) participating in the reaction. Since superoxide dismutase (SOD) is the main defense enzyme against free radical damage, this imbalance between SOD-managed ROS and cellular antioxidant capacity results in hepatic oxidative stress. MDA, the main product of lipid peroxide degradation, promotes inflammation.

[0108] The liver MDA and SOD contents of each group are shown in Table 3. Compared with the blank group, the SOD content of the model group decreased significantly and the MDA content increased significantly, indicating that there is lipid metabolism disorder and liver oxidative stress in the mice. Compared with the model group, the SOD content of Examples 1-5 increased significantly and the MDA content decreased significantly, indicating that the composition provided by the present invention can effectively improve liver oxidative stress caused by lipid metabolism disorder through the synergistic effect of upregulating SOD enzyme activity and downregulating MDA content.

[0109] The difference between Comparative Examples 1-4 and Example 1 lies in the combination of three raw materials. As shown in Table 3, the MDA content was significantly higher than that in Example 1, while the SOD content was significantly lower. This indicates that the combination of four raw materials works synergistically to better reduce the MDA content and increase the SOD content in mouse liver. The difference between Comparative Example 5 and Example 1 is that the proportion of Ganoderma lucidum powder was increased. The SOD content was significantly lower than that in Example 1, while the MDA content was not significantly different from that in Example 1, but the value was higher. This indicates that a higher content of Ganoderma lucidum powder is not necessarily better. Only when it is combined with lemon concentrate, eggshell membrane extract, and beetroot powder in an appropriate proportion can it better exert its effect of reducing MDA and increasing SOD content in mouse liver. The difference between Comparative Example 6 and Example 1 is that the proportion of lemon concentrate powder was increased. The SOD content was significantly lower than that of Example 1, and the MDA content was significantly higher than that of Example 1. This indicates that the four raw materials can better exert their effects of reducing MDA and increasing SOD content in mouse liver when there is a certain ratio range. The difference between Comparative Example 7 and Example 1 is that Astragalus powder was used instead of beetroot powder. Its SOD content was significantly lower than that of Example 1, and its MDA content was significantly higher than that of Example 1. This indicates that the combination of the four raw materials selected in this invention—eggshell membrane extract, lemon concentrate powder, Ganoderma lucidum powder, and beetroot powder—can better exert its effect of alleviating oxidative stress. The raw material composition and ratio selected in this invention are the optimal combination.

[0110] In summary, the composition provided by this invention can reduce the rate of weight change and liver index in mice, and effectively alleviate liver damage by reducing serum AST and ALT levels; reduce liver TG and TC levels to reduce fat accumulation and improve lipid metabolism disorders; increase SOD levels and decrease MDA levels to improve liver oxidative stress caused by lipid metabolism disorders, thereby effectively alleviating non-alcoholic fatty liver disease.

[0111] Table 3. MDA and SOD content in liver tissue

[0112]

[0113] Note: Compared with the blank group, #P<0.05, ##P<0.01; compared with the model group, +P<0.05, ++P<0.01; compared with Example 1, △P<0.05, △△P<0.01.

[0114] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A composition having the effect of preventing and / or improving non-alcoholic fatty liver disease, characterized in that, It includes eggshell membrane extract, lemon concentrate powder, Ganoderma lucidum powder, and beetroot powder.

2. The composition according to claim 1, which has the effect of preventing and / or improving non-alcoholic fatty liver disease, is characterized in that, By weight, it includes 30-50 parts eggshell membrane extract, 5-15 parts lemon concentrate powder, 20-40 parts Ganoderma lucidum powder, and 15-35 parts beetroot powder.

3. The composition according to claim 1 or 2, having the effect of preventing and / or improving non-alcoholic fatty liver disease, is characterized in that, By weight, it includes 35-45 parts eggshell membrane extract, 8-12 parts lemon concentrate powder, 25-35 parts Ganoderma lucidum powder and 20-30 parts beetroot powder.

4. The composition according to claim 2, which has the effect of preventing and / or improving non-alcoholic fatty liver disease, is characterized in that, The weight ratio of the eggshell membrane extract to the lemon concentrate is (2-10):

1.

5. The composition according to claim 2, having the effect of preventing and / or improving non-alcoholic fatty liver disease, is characterized in that, The weight ratio of the eggshell membrane extract to the Ganoderma lucidum powder is (0.75-2.5):

1.

6. The composition according to claim 2, having the effect of preventing and / or improving non-alcoholic fatty liver disease, is characterized in that, The weight ratio of the eggshell membrane extract to the beetroot powder is (0.85-3.3):

1.

7. The composition according to claim 3, having the effect of preventing and / or improving non-alcoholic fatty liver disease, is characterized in that, By weight, it includes 40 parts eggshell membrane extract, 10 parts lemon concentrate powder, 30 parts Ganoderma lucidum powder and 25 parts beetroot powder.

8. The composition according to claim 1, having the effect of preventing and / or improving non-alcoholic fatty liver disease, is characterized in that, The total amino acid content in the eggshell membrane extract is not less than 34g / 100g; The lemon concentrate contains no less than 10% sucralose. The polysaccharide content in the Ganoderma lucidum powder is not less than 10%.

9. A composition for preparing the effects of preventing and / or improving non-alcoholic fatty liver disease as described in any one of claims 1-8, characterized in that, The steps are as follows: weigh the eggshell membrane extract, lemon concentrate powder, Ganoderma lucidum powder, and beetroot powder, mix them, and then sterilize them with ultraviolet light to obtain the composition.

10. The use of the composition according to any one of claims 1-8 and the composition obtained by the preparation method according to claim 9 in the preparation of products for the prevention and / or improvement of non-alcoholic fatty liver disease.

Images